2021 Earnings Call Summary for Labcorp

Labcorp reported strong results in the third quarter of 2021, with revenue totaling $4.1 billion, adjusted earnings per share reaching $6.82, and free cash flow of $650 million. The company's Base Business for both Diagnostics and Drug Development performed well, with 10% and 22% growth, respectively. COVID testing volumes were higher than anticipated, with an average of 85,000 tests per day in the quarter. Labcorp continues to support the fight against the pandemic through both its diagnostic and drug development capabilities. The company has received Emergency Use Authorization for a combined COVID and flu-at-home collection kit and collaborated with AstraZeneca on a COVID prevention and treatment trial. Labcorp is also working on bringing new innovations to market, including a combined COVID and flu-at-home collection kit and collaborations with AstraZeneca and Merck on COVID prevention and treatment trials. The company is raising full year guidance for revenue, adjusted earnings per share, and free cash flow based on its strong performance and improved outlook.